137 related articles for article (PubMed ID: 29108297)
1. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Lee JM; Hays JL; Chiou VL; Annunziata CM; Swisher EM; Harrell MI; Yu M; Gordon N; Sissung TM; Ji J; Figg WD; Minasian L; Lipkowitz S; Wood BJ; Doroshow J; Kohn EC
Oncotarget; 2017 Oct; 8(45):79175-79187. PubMed ID: 29108297
[TBL] [Abstract][Full Text] [Related]
2. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Lee JM; Hays JL; Annunziata CM; Noonan AM; Minasian L; Zujewski JA; Yu M; Gordon N; Ji J; Sissung TM; Figg WD; Azad N; Wood BJ; Doroshow J; Kohn EC
J Natl Cancer Inst; 2014 Jun; 106(6):dju089. PubMed ID: 24842883
[TBL] [Abstract][Full Text] [Related]
3. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Lampert EJ; Hays JL; Kohn EC; Annunziata CM; Minasian L; Yu M; Gordon N; Sissung TM; Chiou VL; Figg WD; Houston N; Lee JM
Oncotarget; 2019 Apr; 10(30):2855-2868. PubMed ID: 31080557
[No Abstract] [Full Text] [Related]
4. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
[No Abstract] [Full Text] [Related]
5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
6. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Geenen JJJ; Dackus GMHE; Schouten PC; Pluim D; Marchetti S; Sonke GS; Jóźwiak K; Huitema ADR; Beijnen JH; Schellens JHM; Linn SC
Int J Cancer; 2021 Jun; 148(12):3041-3050. PubMed ID: 33539540
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Rivkin SE; Moon J; Iriarte DS; Bailey E; Sloan HL; Goodman GE; BonDurant AE; Velijovich D; Wahl T; Jiang P; Shah CA; Drescher C; Fer MF; Kaplan HG; Ellis ED
Int J Gynecol Cancer; 2019 Feb; 29(2):325-333. PubMed ID: 30700568
[TBL] [Abstract][Full Text] [Related]
8. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
van der Noll R; Marchetti S; Steeghs N; Beijnen JH; Mergui-Roelvink MW; Harms E; Rehorst H; Sonke GS; Schellens JH
Br J Cancer; 2015 Jul; 113(3):396-402. PubMed ID: 26180927
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
12. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
15. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
Lee JD; Ryu WJ; Han HJ; Kim TY; Kim MH; Sohn J
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626017
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Gatti-Mays ME; Karzai FH; Soltani SN; Zimmer A; Green JE; Lee MJ; Trepel JB; Yuno A; Lipkowitz S; Nair J; McCoy A; Lee JM
Oncologist; 2020 Dec; 25(12):1013-e1824. PubMed ID: 32510664
[TBL] [Abstract][Full Text] [Related]
18. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F; Corona SP; Giudici F; Strina C; Sirico M; Bernocchi O; Milani M; Ziglioli N; Aguggini S; Azzini C; Barbieri G; Cervoni V; Cappelletti MR; Molteni A; Lazzari MC; Ferrero G; Ungari M; Marasco E; Bruson A; Xumerle L; Zago E; Cerra D; Loddo M; Williams GH; Paris I; Scambia G; Generali D
Front Oncol; 2021; 11():686776. PubMed ID: 34262869
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
